HENDERSON, NV – June 12, 2025, www.L2Bio.com – L2 Bio, is the clear leader in adipose-derived stem cell banking. L2 Bio is the only AD-Stem Cell Banking company with an FDA Approved Investigational New Drug. L2 is actively recruiting qualified Principal Investigators for its recently FDA-approved Phase 2B clinical trial. This groundbreaking study will investigate a novel intravenous (IV) delivery of adipose-derived stem cells (ADSCs or ASCs) for the treatment of Crohn’s Disease utilizing autologous or first-degree blood relative sourced Adipose Derived Mesenchymal Stem Cells (AD-MSCs). A simple, virtually painless, 15-minute procedure from the subject or donor is likely to produce enough stem cells to treat the subject for the duration of the trial and likely the remainder of their life if necessary. [Read more…]
Setting the Standard in Adipose-Derived Stem Cell Applications
This article is part two of my interview with Matthew Feshbach, CEO and Co-Founder of Okyanos (pronounced “Oh – key – AH – nos”). Founded in 2011, Okyanos specializes in treating patients with chronic, degenerative conditions. Located in Freeport, Grand Bahama, just 55 miles from the United States, Okyanos Cell Therapy combines a blend of stem and regenerative cells derived from a patient’s own adipose (fat) tissue. [Read more…]
Okyanos – Adipose-Derived Stem Cell Treatments with CEO Matt Feshbach
Founded in 2011, Okyanos (pronounced “Oh – key – AH – nos”) is an innovative stem cell therapy provider that specializes in treating patients with congestive heart failure (CHF) and other chronic conditions. The literary name Okyanos, the Greek God of the river Okyanos, symbolizes the restoration of blood flow. Okyanos Cell Therapy delivers a mixed population of fat (adipose) derived stem and regenerative cells (ADRCs) using internationally-approved technology to patients with chronic, degenerative conditions. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. [Read more…]